Hyperpolarized carbon-13 mri for early response assessment of neoadjuvant chemotherapy in breast cancer patients

HIGHLIGHTS

• who: Anil Negi from the Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for, %-40% of patients with operable early-stage breast cancer, particularly patients with HER2-positive (HER2-) and , Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom Department of Radiology, University of Cambridge, Cambridge, United Kingdom. Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom. MRC Biostatistics . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.